Research Labs

Yael David’s lab develops and applies methods in chemical biology toward studying epigenetic regulation and its correlation with disease states.

Medical Physics Department Chair Joseph Deasy focuses on integration and analysis of dose, imaging, and molecular data to predict outcomes and guide personalized treatments.

Physician-scientist Liang Deng studies poxvirus interface with the immune system and the development of poxviruses as oncolytic and immunotherapy for cancers.

The Kushal Dey lab focuses on developing machine learning models and computational pipelines that integrate genomic and epigenomic data.

Our team is focused on developing novel tools and approaches for the diagnosis and treatment of cancer using genomics as a guide.

The Diehl lab studies how the microbiota and other exogenous factors regulate development and function of the intestinal immune system.

The Diver lab studies the physiological roles and molecular mechanisms of understudied membrane-embedded proteins with the goal of revealing novel therapeutic targets for diseases such as pain and cancer.

Dr. Ahmet Dogan is a board-certified pathologist and an internationally recognized leader in hematopathology. His current research interests include lymphoma, plasma cell disorders, and diagnostic techniques for hematopathology such as cytogenetic analysis, genomics, and proteomics. His previous work has contributed much to the understanding of the histogenesis of lymphomas, MALT lymphomas, and T cell lymphomas in particular.

My research involves the elucidation of genetic and biologic insights of human malignant lymphomas. We leverage large-scale unbiased profiling including genomics, transcriptomics, proteomics to identify candidate oncogenes and proteins that are pathogenetically relevant in lymphoma. We utilize molecular technologies, human tumor tissues and patient-derived xenografts and transgenic animal models to determine the functional significance of novel genes and proteins involved in lymphoma pathogenesis. Using primary tumors as our discovery models, the overall goal of our studies is to understand novel mechanisms of oncogenesis, identify tumor biomarkers and vulnerabilities that will facilitate early detection and precision therapies that improve patient outcomes.

Physician-scientist James Fagin focuses on the pathogenesis of thyroid cancer and the role of oncogenic kinases.